| 5.09 -0.15 (-2.86%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.32  |
1-year : | 6.9 |
| Resists | First : | 5.41 |
Second : | 5.9 |
| Pivot price | 5.22  |
|||
| Supports | First : | 4.62 |
Second : | 3.84 |
| MAs | MA(5) : | 5.05 |
MA(20) : | 5.22 |
| MA(100) : | 4.26 |
MA(250) : | 8.59 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 20.9 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 15.05 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EMBC ] has closed above bottom band by 38.5%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.29 - 5.32 | 5.32 - 5.35 |
| Low: | 4.97 - 5 | 5 - 5.03 |
| Close: | 5.04 - 5.1 | 5.1 - 5.14 |
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Fri, 04 Sep 2026
Embecta (NASDAQ: EMBC) director files to sell $36,891 in stock - stocktitan.net
Mon, 31 Aug 2026
embecta to Participate in Investor Events - Yahoo Finance
Mon, 31 Aug 2026
embecta plans meetings with investors in Boston and Nashville - stocktitan.net
Wed, 26 Aug 2026
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - newsfilecorp.com
Wed, 15 Jul 2026
Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 57 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 92.3 (%) |
| Shares Short | 5,440 (K) |
| Shares Short P.Month | 6,030 (K) |
| EPS | 1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -10.82 |
| Profit Margin | 8.5 % |
| Operating Margin | 23.6 % |
| Return on Assets (ttm) | 12.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -8.2 % |
| Gross Profit (p.s.) | 10.5 |
| Sales Per Share | 18 |
| EBITDA (p.s.) | 4.96 |
| Qtrly Earnings Growth | -53.8 % |
| Operating Cash Flow | 174 (M) |
| Levered Free Cash Flow | 138 (M) |
| PE Ratio | 3.46 |
| PEG Ratio | 0 |
| Price to Book value | -0.48 |
| Price to Sales | 0.28 |
| Price to Cash Flow | 1.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|